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Abstract 
A novel dual-imaging cisplatin-carrying molecular cargo capable of performing simultaneous optical 
and MR imaging is reported herein. This long-lasting MRI contrast agent (r1 relaxivity of 23.4 
mM-1s-1 at 3T, 25 oC) is a photo-activated cisplatin prodrug (PtGdL) which enables real-time 
monitoring of anti-cancer efficacy. PtGdL is a model for monitoring the drug delivery and 
anti-cancer efficacy by MRI with a much longer retention time (24 hours) in several organs such as 
renal cortex and spleen than GdDOTA and its motif control GdL. Upon complete release of 
cisplatin, all PtGdL is converted to GdL enabling subsequent MRI analyses of therapy efficacy 
within its reasonably short clearance time of 4 hours. There is also responsive fluorescence 
enhancement for monitoring by photon-excitation. 
Key words: prodrug; multi-modal; MRI; drug delivery; fluorescence imaging; cisplatin. 
Introduction 
Highly cytotoxic platinum (II)/(IV) coordination 
complexes, such as cisplatin and its derivatives, i.e. 
carboplatin/oxaliplatin, are well-known potent 
anticancer agents (1-5). Their pharmacologically 
inactive forms, otherwise termed as prodrugs, have 
been developed for optimizing their drug delivery 
process, e.g. tumor selectivity, water solubility, and 
cell permeability, before subsequent activation at the 
target sites (6-8). Despite the clinical success of several 
prodrugs, unprecedented challenges remain in 
achieving their desired pharmacokinetics with 
minimal adverse side effects since they are 
non-specifically distributed throughout the body (9). 
The major drawback of prodrugs, according to the 
literature, lies in the difficulties of tracing their 
activities in vitro/in vivo (10-11). Intriguingly, the 
recent advent of theranostic nanomedicine – an 
emerging paradigm combining diagnostic and 
therapeutic entities into one – creates a new research 
landscape and provides a promising solution to the 
prodrug conundrum (12-14). 
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Figure 1. Schematic illustration of the photo-induced cleavage of the multi-modal long-lasting MRI contrast agent (PtGdL) to generate a fast clearance MRI probe 
(GdL) simultaneously showing highly fluorescent off–on signals and cytotoxic effects. 
 
Novel theranostic technology affords 
simultaneous imaging diagnosis and targeted therapy 
for diseases (15-17). For instance, theranostic 
nanoagents of diagnostic capability and therapeutic 
efficacy can be utilized in pathological mechanistic 
studies and guided pre-/post-treatment assessments 
due to their responsive signaling, e.g. magnetic 
resonance (MR) and fluorescence in vitro/in vivo 
(18-20). The biodistribution characteristics of a 
theranostic scaffold in vivo are necessary to be 
recorded to assess the efficiency of drug or probe 
delivery to pathological tissues. Such agents would 
allow us to control the drug release with the 
fluorescence excitation and monitor the drug‘s 
therapeutic effect with the emission of the prodrug 
(21-22). Borrowing the concept from their 
nano-counterparts, our goal is to develop theranostic 
molecular prodrugs. Recently, we reported a 
proof-of-concept study on our newly designed 
platinum-europium complex (PtEuL) which holds 
great promise as a controlled delivery vehicle of 
cisplatin. It shows real-time, responsive 
photo-triggered ‘off-on’ lanthanide-based long-lived 
fingerprint emission during the drug delivery to 
therapeutic process in vitro once cisplatin is 
photo-dissociated (23). However, deep penetration in 
vivo imaging, such as in internal organs, with the 
previous methodology is impossible. Our present goal 
of developing a dual-imaging cisplatin-carrying 
molecular cargo capable of performing simultaneous 
optical and MR imaging, i.e. synergistic sensitive and 
high temporal-spatial resolution, will help scientists 
to study the real-time biodistribution and 
pharmacokinetics in situ more comprehensively and 
conveniently. In addition, this complex will assist the 
evaluation of the performance of the prodrug without 
interference from autofluorescence, not to mention the 
advantage of avoiding tedious control experiments 
(24-26). 
Herein, we have achieved the breakthrough of 
an ‘all-in-one’ fluorescence imaging, MRI and 
photo-dissociable theranostic agent PtGdL (Figure 1) 
with much larger r1 relaxivity (23.4 mM-1s-1, 3T, 25°C) 
and longer retention (24 hours) MR imaging 
compared to GdDOTA and GdL (controls). The 
longer retention time in renal cortex (i.e. between 4-18 
hours) provides the duration for the cisplatin from 
PtGdL to be released, enabling anti-cancer therapy 
(conditions) via photon irradiation. Following this, 
PtGdL is converted to the fast clearance motif form, 
GdL, allowing further therapy analysis and is cleared 
over a short period of time. 
Results and Discussion 
Photophysical and photochemical properties 
of the prodrug PtGdL 
The solution-state electronic adsorption and 
emission spectra of GdL and PtGdL were determined 
at 298 K in aqueous solution. The GdL complex is the 
proposed product of PtGdL after photo-irradiation 
and was used to monitor the photo-induced delivery 
of [Pt–(NH3)2Cl]+ from PtGdL. The absorption bands 
of PtGdL and GdL are located at ca. 327 and 324 nm 
respectively (Figure 2A). GdL exhibited relatively 
strong blue emission peaking at around 426 nm, with 
3 % quantum yield, in aqueous solution, which is 
attributed to the ligand fluorescence. PtGdL is 
non-emissive since the excited states (singlet excited 
state S1 or triplet excited state T1) of the ligand 
chromophore are quenched by the cisplatin moiety. 
The energy transfer and quenching mechanism of the 
platinum moiety to the organic chromophore of 
PtGdL is similar compared with our previous study 
of PtEuL (23). In PtGdL, the energy absorbed by the 
organic chromophore is transferred to the dissociative 
state (23) of the cisplatin moiety in PtGdL, which 
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weakens the Py–Pt coordination bond, and 
subsequently results in the dissociation of the 
cisplatin moiety instead of generating fluorescence. 
The difference in photophysical property of GdL and 
PtGdL offers a responsive emission signal change 
upon UV or two-photon excitation of the PtGdL 
complex, resulting in the delivery of cisplatin moiety 
and GdL from the complex PtGdL. Photo-activation 
of PtGdL in tris buffer solution is shown in Figure 2C. 
The pseudo-first order rate constant k for the 
dissociation of the cisplatin unit in PtGdL is 0.051 
min-1, which is similar to our reported motif complex 
PtEuL (ks = 0.053 min-1, under same conditions as 
PtGdL) (23). The emission intensity of the organic 
antenna of PtGdL was enhanced 48-fold after the 
photo-release of the cisplatin unit from PtGdL. 
In vitro two-photon imaging and in vitro/in vivo 
photodynamic therapeutic effects of PtGdL 
The dark toxicity of the PtGdL complex was 
evaluated in a cancer cell line (HeLa) and a normal 
cell line (WPMY-1) (Table S3 and Figure S3). PtGdL 
showed lower dark toxicity compared to pure 
cisplatin over 24 hours (IC50 of cisplatin in HeLa = 
~3.3 ± 0.3 μM and WPMY-1 = 4.2 ± 0.6 μM; PtGdL in 
HeLa = ~23.6 ± 0.8 μM and WPMY-1 = 43.9 ± 1.1 μM). 
The UVA (365 nm, 1Jcm-2) induced photo-cytotoxicity 
of PtGdL is about seven times higher than its dark 
toxicity (light IC50 of PtGdL in HeLa = ~3.8 ± 0.7 μM 
and WPMY-1 = ~6.9 ± 1.1 μM) and it is comparable 
with the dark cytotoxicity of cisplatin in HeLa and 
WPMY-1 cells. In the control experiments, cisplatin 
and GdL show similar photo cytotoxicity to their dark 
cytotoxicity. However UV light suffers from 
disadvantages such as short penetration depth and 
DNA damage of UV light itself. The 
photo-cytotoxicity of PtGdL was further investigated 
on a Leica SP8 (upright configuration) confocal 
microscope equipped with an NIR femtosecond laser. 
Real-time photo-release of cisplatin from PtGdL in 
HeLa can be monitored and image by the 
photo-induced responsive emission during the 
photoactivation of PtGdL. For photo-cytotoxicity, the 
two-photon in vitro imaging and photo-release of 
cisplatin in human cervical cancer cells (HeLa) were 
investigated on a Leica SP8 (upright configuration) 
confocal microscope equipped with a femtosecond 
laser. The blue-green emission from the cells treated 
with PtGdL was observed in the cytoplasm with 
significant toxicity at the excitation of 730 nm laser for 
30 min (420 mW power within 30 min, 5 min duration, 
steady temperature = 37 oC ± 1.5 oC). Dramatic cell 
death can be observed with less than 5 µM dosage 
concentration with PtGdL, however, the dark IC50 of 
PtGdL against HeLa cells is ~23.6 µM under the same 
experimental conditions (Figure 3 and Figure S3). 
Control experiments were performed with GdL under 
the same experimental conditions and no significant 
cell death was observed from either GdL treatment or 
laser irradiation. 
 
 
Figure 2. Photophysical and photochemical properties of PtGdL and GdL in tris buffer solution: Absorption (A, 10 µM) and emission spectra (B, 3 µM, λex = 330 
nm) of PtGdL and GdL; Emission spectra variation of 3 µM of PtGdL (C) in tris buffer solution (20 mM tris base, 50 mM NaCl, pH 7.4) with irradiation of 365 nm 
UV light. (D) Plot of I/I0 @ 426 nm vs. time. Pseudo-first order rate constant for the dissociation of PtGdL is 0.051 min-1. 
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Figure 3. Two-photon (λex = 730 nm) induced images and cell death of HeLa cells incubated with PtGdL at different dose concentrations (1, 2, 5, 10 µM) for 24 h. 
(A) Without irradiation, there is no blue emission; (B) after 30 min excitation, blue emission from released GdL was observed; (C) Merged images of (B) and bright 
field of (A) shows significant cell death and blue emission intensity from the cells treated with PtGdL and 730 nm laser (Remark : IC50 of PtGdL in HeLa cells is 23.6 
± 0.8 μM). 
 
To evaluate the in vivo photodynamic anticancer 
ability of PtGdL, intra-tumoral injections of PBS 
buffer, cisplatin (2.5 mg per kg) and PtGdL (9.6 mg 
per kg) were administered to HeLa cell xenografts in 
BALB/c nude mice. The injections were carried out 
once every two days in the dark. The tumor treated 
with PtGdL was irradiated with 365 nm UVA (10 
mW) for 30 min after 30 min of the injection. After 
irradiation of UVA, the mice were returned to dark. 
The treatments continued for 14 days. At the end of 
the experiment, the mice were killed and the tumors 
were excised and weighed. PtGdL with UVA 
irradiation showed comparable tumor growth 
inhibition compared to the tumor injected with PBS 
buffer (the size and the mass of the tumor are reduced 
to about one-third comparing with the tumor injected 
with PBS buffer). The experiments demonstrated that 
our prodrug PtGdL with UVA irradiation has similar 
anticancer effects with cisplatin. (Figure S4)  
The T1 relaxivity of PtGdL 
One of the key breakthroughs of this work 
features the magnetic properties of PtGdL. The r1 
relativity of the proposed MR-available prodrug - 
PtGdL - has been measured and surprisingly, the 
relaxivity at 3T was six times greater than Gd-DOTA 
(Figure 4). The efficacy of PtGdL as a potential MRI 
contrast agent was evaluated by proton nuclear 
magnetic relaxation dispersion (NMRD). The proton 
NMRD profiles of the relaxivity – defined as the 
enhancement of longitudinal relaxation rate by 1 mM 
of a Gd(III) complex – of PtGdL, GdL and Gd-DOTA 
are shown in Figure 4. The profiles were run at 25 and 
37°C, and the concentrations of the samples were 
confirmed by ICP-MS. Moreover, a high preliminary 
r1 relaxivity of PtGdL of 23.4 mM-1s-1 was also 
measured at 3T (25°C), demonstrating its potential to 
be used as a T1- weighted MRI contrast agent. The T1 
relaxation time of a set of 5 solutions of PtGdL of 
different concentrations was measured in a 3T Philips 
Achieva scanner. The concentration of the solutions 
was confirmed by ICP-MS and the relaxivity was 
determined by the plot of the relaxation rate (R1, s-1) as 
the function of the Gd(III) concentration in mM 
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(Figure S5, Table S4). The observed relaxivities for 
both GdL and PtGdL are unexpectedly high. We 
believe that these increased relaxivities are due to an 
aggregation of the compounds in solution, which 
results from the isonicotinamide group, leading to a 
stacking effect of the molecules. This effect becomes 
even more remarkable in the presence of the cisplatin 
unit – leading to an additional increase in the 
relaxivity of PtGdL when compared to GdL: 29.4 vs 
23.1 mM-1s-1 at 10 MHz (0.25T) and 25 °C. The DLS 
measurement of an aqueous solution of PtGdL 
showed the presence of aggregates e.g. 672 ± 24 nm 
(single peak, PDI 0.156; Figure S6), which suggests 
that the increasing effect comes from high rotational 
correlation times due to the presence of aggregates in 
solution (27-30). The related compounds 
Gd-DO3A-(4-morpholinopyridine) and the 
Gd-DTPA-(cisplatin-pyridine-2-ylmethanamine), 
reported in the literature, show a relaxivity of 5.3 
mM-1s-1 (20 MHz and 25°C) and 6.5 mM-1s-1 (20 MHz, 
37°C) respectively (31-32). The coordination sphere of 
the Gd(III) in our novel compounds and in the 
literature analogs is the same, featuring one water 
molecule (Table S2). The presence of the cisplatin unit 
directly conjugated to the pyridine only leads to a 
small increase of the relaxivity when compared to 
Gd-DOTA. These facts help support our conclusion 
that the increased relaxivities of our compounds 
result from the additional isonicotinamide group. 
 
 
Figure 4. NMRD profiles of PtGdL, GdL and Gd-DOTA (1 mM) at different 
magnetic field strength values, and at 25 oC and 37oC. 
 
MRI studies of PtGdL in vivo 
Based on these interesting results, in vivo 7T MRI 
measurements were performed on normal wild-type 
mice to evaluate biodistribution of the imaging probes 
in different organs and to assess the 
pharmacokinetics. MR images were acquired at 
various time-points in different organs of interest 
(kidney, liver, and spleen) to record the kinetic 
uptake, retention and clearance of contrast agents of 
injected solutions of the commercially available 
Gd-DOTA complex (DOTAREM), GdL and PtGdL. 
The injection doses were, respectively, 210 µmol/kg (4 
µmol/mouse) and 30 µmol/kg (0.6 µmol/mouse). 
After intravascular injection via the caudal vein, the 
uptake phase was visualized from the MR signal 
enhancement observed in the liver and renal cortex. 
GdL was immediately captured by the liver, spleen 
and the kidneys in 10s (Figure 5A and 6A). No specific 
retention was observed in any of the observed tissues. 
Full clearance was observed approximately 4 hours 
post-injection (Figure 5C and 6C). By the clearance 
phase, the signal enhancement of GdL had decreased 
by 90 %, indicating full clearance (Figure 5C). In 
comparison to commercialized Gd-DOTA, GdL 
presented a similar biodistribution pattern in the 
kidneys but a slower clearance rate in the liver (slope 
of signal intensity enhancement in the clearance part 
(0.002 vs 0.016 /min). However, PtGdL, showed a 
slightly delayed capture, longer retention, and slower 
clearance compared to GdL. The uptake delay 
increased from 6 to 9 minutes in the kidney and 9 to 
15 min in the liver (Figures 5B and 6B) indicating 
prolonged retention in the bloodstream of the PtGdL 
relative to the other probes. This result is interesting 
as imaging or theranostic probes should be retained as 
long as possible because they generally have to reach 
their targets via the blood pathway. Hepatic and renal 
retention of about 24 hours was observed for PtGdL. 
The MRI signal enhancement decreased by 90% at 24 
hours, indicating a clearance of the order of one day 
(Figure 5C). This long-lasting clearance may be due to 
an interaction between the cisplatin moiety in PtGdL 
and some proteins (33-37). The liver showed 
discoloration (whitening) compared to the normal 
reddish tissue color (data not shown here). In 
summary, PtGdL presents advantages compared to 
cisplatin-free GdL. In particular, PtGdL has the 
potential to become a new generation of 
MRI-available agents. The controlled photo-triggered 
release of cisplatin from PtGdL can serve as an 
anti-cancer drug delivery vehicle while the efficacy of 
the anti-cancer effects can be simultaneously 
monitored based on the untransformed PtGdL. Upon 
complete cleavage of cisplatin, i.e. complete 
generation of GdL from PtGdL, the remaining GdL is 
cleared within 4 hours, and the fate of cisplatin is 
well-studied in literature. 
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Figure 5. In vivo T1-weighted MR images of mouse liver obtained between 6 minutes and 4 hours post injection for GdL (A) and between 9 minutes and 24 hours post 
injection for PtGdL (B). The signal-decay curves (red line: PtGdL, green line: GdL, blue line: Gd-DOTA) are represented in C. 
 
Conclusions  
In conclusion, we have advanced our previous 
photo-activated theranostic anti-cancer prodrug by 
incorporating excellent MRI capabilities (r1 23.4 
mM-1s-1 at 3T, 25 °C) as a tool for monitoring the 
arrival of the prodrug with low cytotoxicity. We can 
photo-assist release of cisplatin for therapy, with the 
cis-platin released from non-toxic PtGdL being 
observed by the emission of GdL (removal of 
cisplatin). In addition, PtGdL also exhibits longer 
retention time (24 hours) in target organ(s) than the 
cisplatin-free GdL and GdDOTA controls, thus 
allowing a wider timeframe for the released cisplatin 
to perform anti-cancer function and for monitoring. 
Upon completing release of cisplatin, all PtGdL is 
converted to GdL for subsequent responsive MR and 
fluorescence imaging analysis of therapy efficacy and 
biodistribution within its reasonably short clearance 
time of 4 hours. Our next step will focus on 
integrating these multifunctional prodrugs with 
target-specific vectors to enhance their specificity 
towards clinical targets and increasing the overall 
efficiency of the anti-cancer therapy. 
Experimental Section 
Synthesis and characterization of the 
complexes GdL and PtGdL 
The synthesis and characterized in our 
previously work (23). The high performance liquid 
chromatography (HPLC) spectra and the high 
resolution ESI mass spectra of GdL and PtGdL are 
shown in the supporting information Figure S1 and 
S2. 
Photophysical measurements  
UV-Visible absorption spectra in the spectral 
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range 200 to 1100 nm were recorded by an HP Agilent 
UV-8453 spectrophotometer. Emission spectra were 
recorded by using a Horiba Fluorolog-3 
spectrophotometer. (Available for fluorescence 
lifetime and steady state emission measurement - 
equipped with a visible to near-infrared-sensitive 
photomultiplier in nitrogen flow cooled housing). The 
spectra were corrected for detector response and stray 
background light phosphorescence. The absolute 
emission quantum yields of GdL and PtGdL were 
measured by integrated sphere techniques (38). The 
linear light induced dissociation of PtGdL in tris 
buffer (20 mM tris base, 50 mM NaCl, pH 7.4) was 
monitored by determination of the emission spectra of 
solution of PtGdL in tris buffer with different light 
dosage of 365 nm UV light. 3 mL of the solution of 
PtGdL (3 µM in tris buffer) in a 3.5 mL quartz cuvette 
was irradiated with a 365 nm UV lamp (5 mW) with 
stirring. The emission spectra of the solution were 
recorded at different time points (0, 1, 3, 5, 7, 10, 15, 20, 
30, 45, 60, 75 and 90 min). The data were processed 
with OriginLab Origin 6.0. The plot of I/I0 @ 426 nm 
vs. time (Figure 2.) fits the equation: 
y = y0 + A e-kt  
to obtain the pseudo-first order rate constant k 
(39). Where I0 and I are the initial emission intensity 
and the emission intensity after period of time t of UV 
light irradiation respectively. 
 
 
Figure 6. In vivo T1-weighted MR images of mouse renal cortex between 6 minutes and 4 hours for GdL (A) and between 9 minutes and 24 hours for PtGdL (B). 
Signal-decay curves (red line: PtGdL, green line: GdL, blue line: Gd-DOTA) are represented in (C). 
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T1 relaxivity measurements 
The 1/T1 nuclear magnetic relaxation dispersion 
(NMRD) profiles of Gd-DOTA, GdL and PtGdL 
(1mM) were recorded at 37 oC and 25 oC on a Stelar 
SMARtracer FFC fast-field-cycling relaxometer 
covering magnetic fields from 2.35 x 10-4 T to 0.25 T, 
which corresponds to a proton Larmor frequency 
range of 0.01-10 MHz. The temperature was 
controlled by a VTC91 temperature control unit and 
maintained by a gas flow. The temperature was 
determined according to previous calibration with a 
Pt resistance temperature probe. The accurate 
concentration of the solutions was determined by 
Inductively Coupled Plasma Mass Spectrometry 
(ICP-MS). 
A set of 5 solutions with concentrations 5.4 µM to 
0.1 mM were prepared and their Gd(III) concentration 
confirmed by ICP-MS, measured in a PerkinElmer 
NexION 350D spectrometer. The T1 values of these 
solutions were measured in a 3 T Philips Achieva 
scanner (25 °C), using a MOLLI sequence. The T1 
value used for the determination of the relaxivity is 
the average of 3 slices for each sample. 
Cell culture 
Human cervical cancer HeLa cells were grown in 
Dulbecco’s Modiﬁed Eagle Medium (DMEM). Human 
prostate stromal - WPMY-1 cells were obtained from 
the cell resource center of Shanghai Institute of 
Biological Sciences, Chinese Academy of Sciences. 
WPMY-1 is growth in MEM (GIBCO 41500034) and 
supplemented with 10% (v/v) fetal bovine serum, 1% 
penicillin and streptomycin at 37 oC and 5 % CO2. 
MTT cell cytotoxicity assays 
For the dark cytotoxicity, HeLa or WPMY-1 cells 
were treated with testing complexes for 24 hours at 6 
concentrations (0, 1, 5, 10, 20 and 40 µM). The cell 
monolayers were rinsed with phosphate buffer saline 
(PBS) once and incubated with 0.5 mg/mL MTT (3-(4, 
5-dimethylthiazol-2-yl)-2 and 5-diphenyltetrazolium 
bromide) solution. The cellular inhibitory potency of 
the complexes was examined by the formation of 
formazan after addition of MTT for 3 hours to allow 
formazan production during cell metabolism. After 
that, formazan was fully dissolved in DMSO through 
oscillation. Finally, the absorbance of solution was 
measured with Biotek Power wave xsMicroplate 
Reader at the wavelength of 570 nm and 690 nm. 
For the Photo-cytotoxicity, HeLa or WPMY-1 
cells (3 x 103) were treated with testing complexes for 
24 hours at 6 concentrations (0, 1, 5, 10, 20 and 40 µM). 
Afterward, the cells were exposed to UVA light (365 
nm, 1 J/cm2). Cell viability was determined by the 
MTT reduction assay at 24-hour post light irradiation. 
Two-photon induced activation and 
fluorescence in vitro imaging 
The cells were incubated with PtGdL (1, 2, 5, 10 
μM) for 12 hours. The complexes (cell impermeable 
and dissolved in the medium) were washed out with 
PBS buffer. The cells with complexes were placed in a 
tissue culture chamber (5% CO2, 37 oC) inside the 
two-photon confocal microscope. In vitro images were 
captured by using the Leica SP8 (upright 
configuration) confocal microscope which was 
equipped with a femto-second laser (wavelength: 700 
to 1000 nm) and 40x/60x oil immersion objective. The 
in vitro images were taken after 30 min laser excitation 
(λex = 700 nm, Power = 420 mW, each 5 min with 1 
min laser excitation, steady temperature = 37oC ± 
1.5oC ). 
Photo-induced in vivo tumor inhibition of 
PtGdL 
Hela xenografts tumor nodules were implanted 
subcutaneously in the BALB/c nude mice (1 × 107 
HeLa cells in 100 µL). Tumor nodules were allowed to 
grow to the volume about 100 mm3 before initiating 
the treatment. Three mice with tumors in nearly the 
same volume were picked up and used for the 
treatment. Tumor length and width were measured 
with calipers, and the tumor volume was calculated as 
(length × width)2/2. 
T1 weighted in vivo imaging and 
bio-distribution 
Biodistribution studies were conducted on a 7T 
micro MRI system (Bruker, Wissembourg, France) 
equipped with a 1H radiofrequency linear coil 
birdcage probe of 4 cm inner diameter in order to 
assess the uptake and clearance of MRI contrast 
agents (CA) from kidney, muscle, spleen, liver. All 
animal experiments were performed in accordance 
with the institutional animal protocol guidelines in 
place at Paris Descartes University, (saisine 
CEEA34.JS.142.1) and approved by the Institute’s 
Animal Research Committee. 
Wild-type female 8 weeks BALB/c mice 
(Elevage Janvier, Le Genest-St-Isle, France) were 
anaesthetized with isoflurane (1.5%, with air/O2 
0.5/0.25 L.min-1) inhalation and placed in a dedicated 
contention cradle. 300 µL of gadolinium complexes in 
0.9% physiological serum were intravenously injected 
via the tail vein while the mouse was in the scanner.  
The scanning protocol was developed using 
Bruker Paravision 5.1 software. DCE Dynamic 
contrast enhanced sequence was recorded using 
Intragate Flash multislices for motion free artifacts T1 
weighted sequence (TR = 100 ms, TE = 4 ms, alpha = 
80°). The final images have a spatial resolution of 236 
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µm x 236 µm in plane. The total scan time was in the 
order of 3 min 14 s per images. The dynamic 
follow-up was measured during in a scan time of 24 
hours. 
To study the biodistribution of each complex, 
several regions of interest (ROI) were monitored: the 
liver, muscle, spleen, kidney, and vessels. The 
corresponding MRI intensity related to the amount of 
the Gd complex contrast agents and was plotted 
versus time to visualize the uptake and clearance of 
each complex into the organs. Comparison with 
commercial Gd-DOTA (DOTAREM, Guerbet, France) 
was also performed at the corresponding 
concentration of Gd (10 mM). 
Supplementary Material  
Supplementary figures and tables.  
http://www.ntno.org/v01p0186s1.pdf   
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